Skip to main content
HCSG logo

HCSG · Healthcare Services Group Inc

Track HCSG — free
$25.10 +0.41 (+1.66%) At close · Nov 18
Market Cap
$1.69B
Shares
67.43M
Volume · Nov 18 618.8K Avg daily vol (3M) 692.36K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$25.10 Open$24.60 Day$24.50–25.33 52W close$17.19–26.54 Avg vol 30d712K Short int2.5M · 3.7% of shares · 2.7d Short vol45% Last earningsOct 21, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 23

Up next

Feb 10, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Oct 23
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

For the nine months ended September 30, 2026, the Company reported revenue of $1.413 billion, up 3.1%, and net income of $73.6 million. On October 6, 2026, it used approximately $93.5 million to acquire NEXDINE Hospitality.

Revenue $479.6M ▲ 3.3% Net income $24.88M ▼ 42.1% Diluted EPS $0.36 ▼ 39.0%
Read from the MD&A section
Oct 21
Earnings call
Q3 2026 earnings call

Healthcare Services Group, Inc. reported third-quarter revenue of $479.6 million and net income of $24.9 million, acquired Nextine Hospitality, and expects fourth-quarter revenue of $535 to $545 million and 2027 low double-digit growth.

Oct 21
Current report 8-K
Financial results

Healthcare Services Group, Inc. reported third-quarter revenue of $479.6 million, net income and diluted EPS of $24.9 million and $0.36, acquired NEXDINE Hospitality for $93.5 million, and raised its 2027 revenue growth outlook from mid single-digits to low double-digits.

Oct 7
Current report 8-K Events of Oct 6
Entered into a material agreement, Regulation FD disclosure

On October 6, 2026, Healthcare Services Group agreed to acquire NexDine, LLC and Xendella, LLC for approximately $93.5 million, subject to customary adjustments and contingent consideration, using cash on hand.

Read from the first part of this long document
Jul 24
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $470.81M ▲ 2.7% Net income $22.7M Diluted EPS $0.32
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.88B
Trailing 12 months
Net income (TTM)
$104.88M
Trailing 12 months
Revenue growth YoY
+3.3%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
17.0
Trailing earnings · reciprocal yield 5.9%
FCF yield
6.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$168.82M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.9%
Year over year · fewer shares
Price change (1Y)
+46.0%
Trailing year
Short interest
3.7%
Latest settlement · 2.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 21, 2026
Q3 FY26

TL;DR. HCSG raised its 2027 growth outlook, expanded through NEXDINE, reported $479.6 million of Q3 revenue, maintained strong liquidity and returned capital through share repurchases. Risks include potentially higher bad debt, workers' compensation volatility, an unresolved Genesis recovery, an expected negative Q4 payroll-accrual impact on reported cash flow and inflation that may not be passed through to customers.

Bullish
  • + HCSG raised its 2027 revenue growth outlook from mid single-digits to low double-digits.
  • + The NEXDINE acquisition is expected to contribute over $150 million in annual revenue at comparable margins and be immediately accretive to earnings.
  • + Q3 revenue was $479.6 million.
  • + Cost of services was 83.2%, benefiting from strong service execution and lower bad debt expense.
  • + HCSG ended Q3 with $204.3 million of cash and marketable securities and an unutilized $300.0 million credit facility.
  • + HCSG repurchased $56.6 million of common stock year to date under its February 2026 plan.
Bearish
  • − Payment delays or customer restructurings could result in significant additional bad debt.
  • − An unpredictable spike in workers' compensation incidents and severity could reverse cost-of-services improvements.
  • − The final Genesis recovery remains subject to unresolved variables and contingencies.
  • − Payroll-accrual timing is expected to have an 18 million dollar negative impact on Q4 reported cash flow.
  • − Continued inflation could adversely affect results if labor, materials, supplies and equipment cost increases cannot be passed on to customers.
  • − The NEXDINE transaction is expected to create an earnings offset from lost interest income on close to $90 to $100 million of cash.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +15%
above
Price vs 50-day avg +10%
above
RSI (14) 58
neutral
MACD trend Negative
52-week position 85%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +16%
trailing
6-month return +22%
trailing
YTD return +31%
this year
Relative strength +25%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $23 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +37 funds added
Insider flow Distributing
Net -$458.0K over 90 days · 100% sells
Short interest Falling
3.68% of shares out · ▼ -8.6% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
279 holders — near 3-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Excellent
Revenue growth +7%
Y/Y
EPS growth +53%
Y/Y
Free cash flow $139.2M
Valuation P/E 17
below peers
Balance sheet $125.2M
net cash
Quant / Vol
risk profile
Moderate
Volatility 42%
annualized · 1-yr
Max drawdown −20%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the 8-K filed Oct 21, 2026
fourth quarter
Fourth quarter revenue $535M – $545M
prior qtr $479.6M midpoint +12.6% QoQ
full-year
Full-year effective tax rate Maintained 25%
Jul 22, 2026 25% changed to Oct 21, 2026 25%
SG&A 9.5% – 10.5%
annual
Annual revenue at least $150M
longer-term goal
SG&A 8.5% – 9.5%
Previous outlook earlier release · from the Earnings Call filed Jul 22, 2026

Still-open targets the latest release did not restate under the same label.

Share repurchases · over 12 months $75M
Cost of sales · not stated 86%
Prior guidance period ended · from the Earnings Call filed Jul 22, 2026
Third-quarter revenue expectations · third quarter $475M – $485M
Guided vs delivered · last 8 settled
Third-quarter revenue expectations third quarter
guided $475M – $485M
$479.6M In line
Q2 revenue Q2
guided $465M – $475M
$470.81M In line
Q1 revenue Q1 2026
guided $460M – $465M
$462.77M In line
Revenue Q3
guided $425M – $435M
$428.15M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+15% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
58 Neutral
MACD trend
Negative Bearish
52-week position
85% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $23 › 200d $22 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +37 funds added
Insider flow Distributing
Net -$458.0K over 90 days · 100% sells
Short interest Falling
3.68% of shares out · ▼ -8.6% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
279 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17 Now $25 · 85% Range high $27
vs 200-day avg +15% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Costs of services provided as a percentage of revenues 84.1% three months ended June 30, 2026 filing —
Dietary labor and labor-related costs as a percentage of segment revenue 58.2% three months ended June 30, 2026 filing —
EVS labor and labor-related costs as a percentage of segment revenue 76.6% three months ended June 30, 2026 filing —
Segment expenses for Dietary as a percentage of Dietary revenues 92.5% three months ended June 30, 2026 filing —
Segment expenses for EVS as a percentage of EVS revenues 86.7% three months ended June 30, 2026 filing —
Segment margin 13.3% Three Months Ended June 30, 2026 filing —
Segment profit $47.63M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HCSG
Healthcare Services Group Inc
this stock
$1.69B +31.3% +7.1% 17.0 3.7%
HCA
HCA Healthcare, Inc.
$99.51B +2.0% +7.1% 15.8 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.07B +2.4% — — 0.0%
THC
Tenet Healthcare Corp
$21.60B +36.5% +0.9% 7.9 2.2%
EHC
Encompass Health Corp
$13.24B +27.1% +10.5% 21.1 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
279
% held
101.6%
Net QoQ
-3.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
339
View
Short & Settlement
Short Interest Falling
Shares short
2.5M
Days to cover
2.7d
Change
-232.9K sh
View
Short Volume
Short vol %
45%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
87
Value
$2.1K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
33.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$458.0K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Greg Gianforte
Amount
$50.0K–$100.0K
Traded
Apr 30, 2020
View
Financials
Financials
Revenue (FY)
$1.8B
Net income (FY)
$59.1M
EPS diluted
$0.81
View
Buybacks
Authorized
shares 10.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 23, 2026
This year
13

For the nine months ended September 30, 2026, the Company reported revenue of $1.413 billion, up 3.1%, and net income of $73.6 million. On October 6, 2026, it used approximately $93.5 million to acquire NEXDINE Hospitality.

View
Proposed Sales
Value
$457.9K
Shares
18.2K
Filed
Oct 26, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 21, 2026
View
Investor Relations
Latest news
Healthcare Services Group Reports…
Published
Oct 21, 2026
View

Performance

5D 20D 120D MTD YTD
HCSG -0.4% +15.6% +21.8% +2.4% +31.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +3.5% +21.2% +25.3% +5.8% +24.2%

Capital returns

Latest dividend
$0.215 / share · ex Nov 17, 2022
Raised 0.5%
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history
Buyback program · as of Feb 10, 2026
Authorized
shares 10.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 731012 CUSIP 421906108 13F (30d) 278 filings 261 filers Visit website Investor relations